Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective

Respirology

Volumn 18, Issue 5, 2013, Pages 765-773

  To, Kin Wang ^c   Reino, Juan J Gomez ^a   Yoo, Dae Hyun ^b   Tam, Lai Shan ^c  

^a University Hospital of Santiago de Compostela   (Spain)

^b Hanyang University College of Medicine   (South Korea)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

diagnosis; rheumatoid arthritis; tuberculosis; tumour necrosis factor antagonist

Indexed keywords

BCG VACCINE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; TUMOR NECROSIS FACTOR INHIBITOR;

ASIAN; BCG VACCINATION; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TUBERCULIN TEST; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; ASIA; DISEASE MANAGEMENT; HUMANS; LATENT TUBERCULOSIS; PREVALENCE; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879336923     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12106     Document Type: Review

References (86)

1. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum. 1993; 36: 1681-1690.
2. Scott DL,. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 2012; 91: 30-43.
3. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003; 48: 2122-2127.
4. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50: 372-379.
5. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005; 52: 1986-1992.
6. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J. Rheumatol. 2007; 34: 706-711.
7. Brassard P, Lowe A-M, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009; 61: 300-304.
8. Tam LS, Leung CC, Ying SK, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clin. Exp. Rheumatol. 2010; 28: 679-685.
9. Baronnet L, Barnetche T, Kahn V, et al. Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review. Joint Bone Spine 2011; 78: 279-284.
10. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009; 60: 1884-1894.
11. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 2010; 69: 522-528.
12. The, Gass RS, Dillon A, et al. The Williamson County Tuberculosis Study. A twenty-four-year epidemiologic study. Am. Rev. Respir. Dis. 1963; 87 (3 Pt 2): 1-88.
13. Comstock GW, Livesay VT, Woolpert SF,. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am. J. Epidemiol. 1974; 99: 131-138.
14. Gomez JE, McKinney JD,. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 2004; 84: 29-44.
15. Tufariello JM, Chan J, Flynn JL,. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 2003; 3: 578-590.
16. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009; 7: 845-855.
17. Pai M, Riley LW, Colford JM Jr,. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect. Dis. 2004; 4: 761-776.
18. Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57: 804-809.
19. Lalvani A, Pareek M,. A 100 year update on diagnosis of tuberculosis infection. Br. Med. Bull. 2010; 93: 69-84.
20. Andersen P, Munk ME, Pollock JM, et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104.
21. Sorensen AL, Nagai S, Houen G, et al. Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 1995; 63: 1710-1717.
22. Diel R, Loddenkemper R, Nienhaus A,. Predictive value of interferon-release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012; 142: 63-75.
23. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur. Respir. J. 2009; 33: 956-973.
24. Diel R, Loddenkemper R, Niemann S, et al. Negative and positive predictive value of a whole-blood interferon-{gamma} release assay for developing active tuberculosis: an update. Am. J. Respir. Crit. Care Med. 2011; 183: 88-95.
25. Kobashi Y, Shimizu H, Ohue Y, et al. Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis. Lung 2010; 188: 283-287.
26. Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 2012; 185: 427-434.
27. Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19: 2038-2041.
28. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J. Acquir. Immune Defic. Syndr. 2011; 56: 230-238.
29. Smolen JS, Steiner G,. Therapeutic strategies for rheumatoid arthritis. Nat. Rev. Drug Discov. 2003; 2: 473-488.
30. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108.
31. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 2008; 117: 244-279.
32. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 2001; 69: 1847-1855.
33. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur. Respir. J. 2010; 36: 1185-1206.
34. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-572.
35. Yamada T, Nakajima A, Inoue E, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann. Rheum. Dis. 2006; 65: 1661-1663.
36. Salgado E, Gomez-Reino JJ,. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev 2011; 7: 329-340.
37. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2009; (4): CD007848.
38. Dryden GW Jr,. Overview of biologic therapy for Crohn's disease. Expert Opin. Biol. Ther. 2009; 9: 967-974.
39. Wallis RS,. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect. Dis. 2008; 8: 601-611.
40. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008; 58: 1248-1257.
41. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 2007; 13: 1323-1332.
42. Spohn G, Guler R, Johansen P, et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 2007; 178: 7450-7457.
43. Olleros ML, Vesin D, Lambou AF, et al. Dominant-negative tumor necrosis factor protects from Mycobacterium bovis Bacillus Calmette Guerin (BCG) and endotoxin-induced liver injury without compromising host immunity to BCG and Mycobacterium tuberculosis. J. Infect. Dis. 2009; 199: 1053-1063.
44. Kirchner S, Holler E, Haffner S, et al. Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes. Cytokine 2004; 28: 67-74.
45. Taylor PC,. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. 2010; 10: 308-315.
46. Dheda K, Smit R, Badri M, et al. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr. Opin. Pulm. Med. 2009; 15: 188-200.
47. World Health Organization. 2012. Tuberculosis country profiles. [Accessed 25 Dec 2012.] Available from URL: http://www.who.int/tb/country/data/profiles/ en/index.html
48. Zhao J, Wang Y, Wang H, et al. Low agreement between the T-SPOT.TB assay and the tuberculin skin test among college students in China. Int. J. Tuberc. Lung Dis. 2011; 15: 134-136.
49. Wu X, Hou Y, Liang Y, et al. Evaluation of a tuberculosis whole-blood interferon-gamma chemiluminescent immunoassay among Chinese military recruits. Mol. Diagn. Ther. 2011; 15: 341-346.
50. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005; 293: 2756-2761.
51. Rangaka MX, Wilkinson KA, Glynn JR, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 2012; 12: 45-55.
52. Hsia EC, Schluger N, Cush JJ, et al. Interferon-release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum. 2012; 64: 2068-2077.
53. Hsia EC, Cush JJ, Matteson EL, et al. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res. 2013; 65: 309-313.
54. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm. Rep. 2010; 59: 1-25.
55. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr. Opin. Rheumatol. 2011; 23: 377-384.
56. Menzies D, Pai M, Comstock G,. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 2007; 146: 340-354.
57. Diel R, Loddenkemper R, Nienhaus A,. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137: 952-968.
58. CC M,. Consensus statements on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong. Hong Kong Bull. Rheum. Dis. 2005; 5: 19-25.
59. Al Jahdali HH, Baharoon S, Abba AA, et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann. Saudi Med. 2010; 30: 38-49.
60. Phanuphak N, Varma JK, Kittikraisak W, et al. Using tuberculin skin test as an entry point to screen for latent and active tuberculosis in Thai people living with HIV. J. Acquir. Immune Defic. Syndr. 2012; 60: 384-392.
61. Gupta KB,. Challenges in diagnosis and treatment of latent tuberculosis infection. Indian J Tuberc. 2012; 59: 1-5.
62. Malaviya AN, Kapoor S, Garg S, et al. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India-An audit report. J. Rheumatol. 2009; 36: 1414-1420.
63. Bartalesi F, Vicidomini S, Goletti D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur. Respir. J. 2009; 33: 586-593.
64. Lioté H, Lioté F,. Role for interferon-gamma release assays in latent tuberculosis screening before TNF-α antagonist therapy. Joint Bone Spine 2011; 78: 352-357.
65. Keystone EC, Papp KA, Wobeser W,. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J. Rheumatol. 2011; 38: 1234-1243.
66. Mariette X, Baron G, Tubach F, et al. Influence of replacing tuberculin skin test with ex vivo interferon release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann. Rheum. Dis. 2012; 71: 1783-1790.
67. Naseer A, Naqvi S, Kampmann B,. Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing. Eur. Respir. J. 2007; 29: 1282-1283.
68. Igari H, Watanabe A, Sato T,. Booster phenomenon of QuantiFERON-TB Gold after prior intradermal PPD injection. Int. J. Tuberc. Lung Dis. 2007; 11: 788-791.
69. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am. J. Respir. Crit. Care Med. 2009; 180: 49-58.
70. Pai M, O'Brien R,. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions? PLoS Med. 2007; 4: e208.
71. Chee CB, KhinMar KW, Gan SH, et al. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am. J. Respir. Crit. Care Med. 2007; 175: 282-287.
72. Higuchi K, Harada N, Mori T,. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008; 13: 468-472.
73. Lee SH, Lew WJ, Kim HJ, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir. Med. 2010; 104: 448-453.
74. Park JH, Seo GY, Lee JS, et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J. Rheumatol. 2009; 36: 2158-2163.
75. Lee SW, Oh DK, Lee SH, et al. Time interval to conversion of interferon-gamma release assay after exposure to tuberculosis. Eur. Respir. J. 2011; 37: 1447-1452.
76. Adetifa IM, Ota MOC, Jeffries DJ, et al. Interferon-[gamma] ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am. J. Respir. Crit. Care Med. 2013; 187: 439-445.
77. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res. Ther. 2006; 8: R114.
78. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur. Respir. J. 2010; 36: 925-949.
79. Malaviya AN, Kapoor S, Garg S, et al. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-α inhibitors in India-followup report. J. Rheumatol. 2010; 37: 209.
80. Chang KC, Leung CC,. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010; 65: 271-276.
81. Lalvani A, Millington KA,. T-cell interferon-gamma release assays: can we do better? Eur. Respir. J. 2008; 32: 1428-1430.
82. Ruhwald M, Bodmer T, Maier C, et al. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 2008; 32: 1607-1615.
83. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52: 1766-1772.
84. Gomez-Reino JJ, Carmona L, Angel Descalzo M, et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 2007; 57: 756-761.
85. Eisenberg RL, Pollock NR,. Low yield of chest radiography in a large tuberculosis screening program. Radiology 2010; 256: 998-1004.
86. Sichletidis L, Settas L, Spyratos D, et al,. Tuberculosis in patients receiving anti-TNF agents despite hemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10: 1127-1132.